SAREUM HOLDINGS PLC

AGM Information • Dec 16, 2022

National Storage Mechanism | Additional information

RNS Number : 0537K

Sareum Holdings PLC

16 December 2022

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Results of AGM

Cambridge, UK, 16 December 2022 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer , held its Annual General Meeting ("AGM") today and all resolutions were duly passed. Details of the voting results are shown in the table below. 

Ordinary Resolutions	Votes For	%	Votes Against	%	Votes Total	% of ISC Voted	Votes Withheld
1. Receive and adopt Report of the Directors and financial statements for the year	6,255,275	99.82	11,023	0.18	6,270,831	9.21	4,533
2. Receive and adopt Renumeration Committee report for the year	5,232,943	85.28	902,951	14.72	6,270,831	9.21	134,937
3. Re-elect Dr John Reader as Director of the Company	6,085,556	98.87	69,338	1.13	6,270,831	9.21	115,937
4. Appoint Shipleys LLP as auditor	5,618,405	91.55	518,753	8.45	6,270,831	9.21	133,673
5. Directors' authority to allot new shares	5,345,322	86.08	864,630	13.92	6,270,831	9.21	60,879
Special Resolution
6. Directors' authority to allot equity securities for cash	5,316,094	85.61	893,858	14.39	6,270,831	9.21	60,879

The full text of each of the resolutions is set out in the Notice of AGM, available in the Investors section of the Company's website (www.sareum.com/investors)

- Ends -

For further information, please contact: 

Sareum Holdings plc Tim Mitchell, CEO / Alex Harrison, Investor Relations	01223 497700
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman	020 7409 3494
Peel Hunt LLP (Joint Corporate Broker) James Steel / Oliver Duckworth	020 7418 8900
Hybridan LLP (Joint Corporate Broker) Claire Noyce	020 3764 2341
Consilium Strategic Communications (Financial PR) Jessica Hodgson / Davide Salvi / Stella Lempidaki	0203 709 5700

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is focused on advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors into clinical development as potential new therapies for autoimmune diseases (with an initial focus on psoriasis), respiratory symptoms arising from viral infections and cancer immunotherapy. Sareum is also eligible to receive certain milestone payments and future royalties on SRA737, a clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. SRA737 was licensed to Sierra Oncology, which was acquired by GSK in June 2022.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGFFEFIMEESEFE